Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...
UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, have engineered a new class of supercharged T cells that are stronger, ...
The Tehachapi CANCER FOUNDATION is inviting local businesses to become sponsors of its signature fundraising event, Screw Cancer 7, taking place on May 2 from 4-8 p.m. at Dorner Family Vineyard, 18274 ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
aDepartment of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany bDepartment of Nuclear Medicine, University Hospital Münster and West German Cancer Center, Münster, Germany ...
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results